In recent days, a number of penny stocks have come onto the radar of investors, and it may be a good time to take a closer look at some of those stocks. However, there may be a large number of stocks, and it may be prudent to be a bit more selective. Here is a quick look at four penny stocks that have been on the radar of investors in recent days.
Golden State Bancorp (OTC:GSBX) The holding company of Golden State Bank, Golden State Bancorp, announced its financial results for the second fiscal quarter of 2023 on Monday. The total assets went up by 10.3% from December 31, 2022, to $715.7 million at the end of the quarter. The loans stood at $552.1 million, which reflected a rise of 8.7% from the figure of $543.2 million at the end of December 31, 2022.
The net income for the quarter was $2 million, and the credit quality continued to be strong. The cash and cash equivalents with Golden State Bancorp at the end of the quarter were $134 million, which reflected a rise of 76% from the figure of $76.1 million under the same overhead as of December 31, 2022. The total deposits went up by 8.2% to touch $607.2 million, as compared to $561.3 million at the end of the period on December 31, 2022. The company ended the quarter with a book value of $21.33 a share.
Mining Global Inc. (OTC:MNGG) On August 8, Mining Global Inc. was in focus after it announced that it had accepted the terms for a merger with a mine in Africa. The company revealed that the merger would be concluded in 30 days from yesterday. The mine in question is located in Namibia.
The company further announced that it had made a supplemental filing with the OTC Markets so as to provide a bird’s-eye view of the merger. The report was supplemented with a mining report running into 85 pages, which included an estimation of the lithium mine exploration project as well. Mining Global also announced yesterday that it continued to operate the VAR mining and trading division and the related mezzanine corporate business services.
Hemostemix Inc. (OTC:HMTXF) Yesterday, Hemostemix Inc. announced that it had submitted its retrospective cardiomyopathy study to a major journal for potential publication. The study is titled “Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Treatment of Cardiomyopathy”. It had been co-authored by a range of experts in the field. The company went on to note that it had also made preparations with regards to its CLI Phase II clinical trial manuscript for peer review and publication. Thomas Smeenk, the Chief Executive Officer of the company, thanked the co-authors of the paper and went on to note that once the paper was accepted, the company would make another announcement.
